asundexian

News

Bayer's asundexian starts EU review for ischaemic stroke

The EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J&J.

News

Bayer reveals data behind asundexian's stroke win

Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic stroke by 26%, according to the OCEANIC-STROKE trial.

News

An older man holds his head in pain while lights flash

Stroke data breathes life back into Bayer's asundexian

Prospects for Bayer's oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.

News

BMS, J&J give up on milvexian for acute coronary syndrome

BMS and J&J call time on oral anticoagulant milvexian in acute coronary syndrome, but are still running trials in atrial fibrillation and stroke.

News

Bayer pulls atrial fibrillation study for asundexian

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded

News

Bayer doubles down on Factor XIa with new phase 3 trial

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixe

Bayer's asundexian starts EU review for ischaemic stroke

Bayer reveals data behind asundexian's stroke win

Stroke data breathes life back into Bayer's asundexian

BMS, J&J give up on milvexian for acute coronary syndrome

Bayer pulls atrial fibrillation study for asundexian

Bayer doubles down on Factor XIa with new phase 3 trial

EMA advisors say CSL's Tavneos should be pulled from sale

Discover a new era of healthcare panel engagement: Grounded ...

asundexian

Editor's Picks